CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 30, 2013
Result type: Reports
Project Number: SR0353-000
Product Line: Reimbursement Review

Generic Name: Riociguat

Brand Name: Adempas

Manufacturer: Bayer Inc.

Therapeutic Area: Chronic thromboembolic pulmonary hypertension

Indications: Pulmonary hypertension, chronic thromboembolic

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 17, 2014

Recommendation Type: List with criteria/condition